Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.
The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback